Yazici Gozde, Akin Serkan, Kahvecioglu Alper, Yigit Ecem, Turker Fatma Alev, Yildiz Ferah
Faculty of Medicine, Department of Radiation Oncology, Hacettepe University, Ankara, Turkey.
Faculty of Medicine, Department of Medical Oncology, Hacettepe University, Ankara, Turkey.
Head Neck. 2025 Mar;47(3):891-898. doi: 10.1002/hed.27976. Epub 2024 Nov 1.
This study evaluates the oncological outcomes and toxicities of indolent ocular adnexal and orbital lymphomas (OOLs) treated with radiotherapy (RT) ± systemic therapy.
A retrospective analysis of 44 patients with indolent OOLs treated with RT was conducted.
Most patients (87%) had early-stage disease. Treatment involved RT alone (34%) or RT + systemic therapy (66%). The median RT dose was 30 Gy, with a median follow-up of 45 months. Local and systemic recurrence rates were 4% and 9%, respectively. Five-year overall and disease-free survival (DFS) rates were 96.2% and 83.6%. Early-stage patients showed similar DFS rates regardless of whether they received RT alone or RT plus systemic therapy. No grade 3 RT-related toxicity occurred, but systemic therapy led to grade 3 toxicity in 17% of patients.
RT is essential for treating indolent OOLs, and combination with systemic therapies does not enhance outcomes for early-stage patients.
本研究评估了接受放疗（RT）±全身治疗的惰性眼附属器和眼眶淋巴瘤（OOL）的肿瘤学结局和毒性。
对44例接受放疗的惰性OOL患者进行回顾性分析。
大多数患者（87%）为早期疾病。治疗方式包括单纯放疗（34%）或放疗+全身治疗（66%）。放疗的中位剂量为30 Gy，中位随访时间为45个月。局部和全身复发率分别为4%和9%。五年总生存率和无病生存率（DFS）分别为96.2%和83.6%。早期患者无论接受单纯放疗还是放疗加全身治疗，DFS率相似。未发生3级放疗相关毒性，但全身治疗导致17%的患者出现3级毒性。
放疗对于治疗惰性OOL至关重要，与全身治疗联合并不能改善早期患者的结局。
